Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc has demonstrated significant potential for growth, as indicated by a 28% increase in stock value following the announcement of Medicare coverage for its NeXT Personal MRD test, which showcases its effectiveness in early cancer recurrence detection. The company's strategic decision to temporarily ease volume growth in Q3 to manage cash burn has positioned it to capitalize on future demand, particularly with anticipated marketing acceleration by its commercial partner Tempus. Furthermore, positive reimbursement outcomes for its breast cancer indication have prompted a reassessment of revenue projections for additional indications, signaling a favorable trajectory for sales estimates into 2026 and beyond.

Bears say

Personalis Inc. faces a negative outlook primarily due to revised revenue expectations, with the company lowering its 2025 revenue guidance from $70-$80 million to $68-$73 million, indicating a year-over-year decline of 5% to 12%. The reduction is attributed to uncertainties in sample flow for minimal residual disease (MRD) testing and delays in reimbursement approvals for clinical sample testing, which are impacting biopharma revenues significantly. Additionally, the company's continued losses and the presence of debt on its balance sheet raise concerns about its ability to achieve and maintain profitability in the future.

Personalis Inc (PSNL) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.